During the past decade, Semmelweis Egyetem Onkologiai Központ conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 8 clinical trials were completed, i.e. on average, 114.3% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 3 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Semmelweis Egyetem Onkologiai Központ" #1 sponsor was "Hoffmann-La Roche" with 9 trials, followed by "Bristol-Myers Squibb" with 1 trials sponsored, "Pfizer" with 1 trials sponsored, "Seagen Inc." with 1 trials sponsored and "Stemline Therapeutics, Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Semmelweis Egyetem Onkologiai Központ" #1 collaborator was "Genentech, Inc." with 2 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator, "Foundation Medicine, Inc." with 1 trials as a collaborator, "Genmab" with 1 trials as a collaborator and "Ono Pharmaceutical Co. Ltd" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Semmelweis Egyetem Onkologiai Központ" are "Breast Cancer" (6 trials), "Gastric Cancer" (2 trials), "Bladder Cancer" (1 trials), "Cancer of Unknown Primary Site" (1 trials) and "Cervix Cancer" (1 trials). Many other conditions were trialed in "Semmelweis Egyetem Onkologiai Központ" in a lesser frequency.

Most popular intervention types in "Semmelweis Egyetem Onkologiai Központ" are "Drug" (12 trials), "Combination Product" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Pertuzumab" (4 trials), "5-Fluorouracil" (3 trials), "Capecitabine" (3 trials), "Trastuzumab" (3 trials) and "Atezolizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Semmelweis Egyetem Onkologiai Központ" are 10 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Semmelweis Egyetem Onkologiai Központ". undefined are not yet recruiting, 1 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Semmelweis Egyetem Onkologiai Központ, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Semmelweis Egyetem Onkologiai Központ, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".